The quantity of data that is currently produced in everyday life and practically in every sector, is...
Matteo Giovanni Della Porta
Associate Professor Hematology MED/15
Head, Leukemia Unit – Cancer Center, Humanitas Research Hospital
Coordinator, SYSTEM-II course – Hunimed Medicine and Surgery university programme
Phone +39 02 8224 7668
He obtained his Medical Degree with honours at the University of Pavia Medical School, Pavia, Italy in 1999. From 2000 to 2003 he completed his training in Hematology at the Department of Hematology, University of Ferrara Medical School, Ferrara, Italy, and obtained his Degree with honours. From 2004 to 2006 he was awarded a postdoctoral fellowship at the Department of Hematology, University of Pavia Medical School & S. Matteo Hospital, Pavia, Italy [Research project: “Genomic and functional characterization of hematopoietic stem cells in myelodysplastic syndromes”.]
Since 2008 he hold the position of Associate Professor of Clinical Oncology at the University of Pavia Medical School & S. Matteo Hospital, Pavia, Italy
Since 2016 he hold the position of Associate Professor of Hematology at Humanitas University, and Head of Leukemia Unit – Cancer Center, Humanitas Research Hospital
Scientific and Research Interests
Current research interests mainly concern acute leukemia, myelodysplastic syndromes and myeloproliferative neoplasms (myeloid malignancies)
These investigations led to the definition of specific gene expression profiles in myelodysplastic syndromes [Blood. 2006;108(1):337-45, Leukemia. 2010;24(4):756-64 and J Clin Oncol 2013;31(28):3557-64: J Clin Oncol. 2016;34(30):3627-3637], to the identification of the molecular basis of refractory anemia with ringed sideroblasts associated with marked thrombocytosis [Blood. 2009;114(17):3538-45], and to the development of the WPSS [J Clin Oncol. 2007;25(23):3503-10 and Blood. 2008;112(3):895-902; Leukemia. 2017;31(11):2449-2457] and the CPSS [Blood. 2013;121(15):3005-15] as a valuable tools for risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative disorders, respectively.
In 2008 he joined the European LeukemiaNet working package on myelodysplastic syndromes, aimed at developing European evidence and consensus-based guidelines for the diagnosis and treatment of myelodysplastic syndromes [Blood. 2013 Oct 24;122(17):2943-64]
In 2010, he joined the International Cancer Genome Consortium Chronic Myeloid Disorders Working Group. This collaboration led to the identification of somatic mutations of SF3B1, a gene encoding a core component of RNA splicing machinery, in myelodysplasia with ring sideroblasts [N Engl J Med. 2011; 365(15):1384-95, Blood. 2011;118(24):6239-46, Blood. 2015 Jul 9;126(2):233-41, Leukemia. 2015 Jan;29(1):66-75].
- Della Porta MG, Jackson CH, Alessandrino EP, Rossi M, et al. Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. Leukemia. 2017 Apr 7. doi: 10.1038/leu.2017.88
- Della Porta MG, Gallì A, Bacigalupo A, et al. Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2016 Sep 6. pii: JCO673616. [Epub ahead of print].
- Della Porta MG, Tuechler H, Malcovati L, et al. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia. 2015 Jul;29(7):1502-13.
- Della Porta MG, Travaglino E, Boveri E, et al . Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia. 2015 Jan;29(1):66-75.
- Della Porta MG, Alessandrino EP, Bacigalupo A, et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood. 2014 Apr 10;123(15):2333-42.